Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.56 |
| ▸ | TERT | O14746 | 1/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.49 |
| ▸ | HPGDS | O60760 | 1/20 | 0.48 |
| ▸ | STS | P08842 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31321884 | 0.89 | GPR119 (0.51) | GPR119TERTNAMPTTHRBKDM4E | |
| SCHEMBL24947192 | 0.89 | GPR119 (0.51) | GPR119TERTNAMPTTHRBKDM4E | |
| SCHEMBL3436365 | 0.87 | GPR119 (0.58) | GPR119NAMPTTHRBKDM4EMAPT | |
| SCHEMBL29709671 | 0.87 | GPR119 (0.49) | GPR119TERTNAMPTTHRBKDM4E | |
| SCHEMBL24793973 | 0.87 | GPR119 (0.49) | GPR119TERTNAMPTTHRBKDM4E | |
| SCHEMBL21953943 | 0.86 | GPR119 (0.56) | GPR119NAMPTTHRBKDM4EMAPT | |
| SCHEMBL16520807 | 0.85 | HPGDS (0.51) | GPR119TERTMAPTHPGDS | |
| SCHEMBL21885666 | 0.85 | GPR119 (0.55) | GPR119NAMPTTHRBKDM4EMAPT | |
| SCHEMBL21352374 | 0.85 | GPR119 (0.55) | GPR119NAMPTTHRBKDM4EMAPT | |
| SCHEMBL73493 | 0.85 | GPR119 (0.55) | GPR119NAMPTTHRBKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024046342-A1 | BENZO BICYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF | 广州市联瑞制药有限公司 | 2024-03-07 | — | — | WO | disclosed |
| US-11773087-B2 | GLP-1R receptor agonist compound and use thereof | SUZHOU VINCENTAGE PHARMA CO., LTD (CN) | 2023-10-03 | — | — | US | disclosed |
| US-11773087-B2 | GLP-1R receptor agonist compound and use thereof | SUZHOU VINCENTAGE PHARMA CO., LTD (CN) | 2023-10-03 | — | — | US | disclosed |
| US-20230257369-A1 | GLP-1R RECEPTOR AGONIST COMPOUND AND USE THEREOF | Chengdu Vincentage Pharma Co., Ltd. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257369-A1 | GLP-1R RECEPTOR AGONIST COMPOUND AND USE THEREOF | Chengdu Vincentage Pharma Co., Ltd. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230212139-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212139-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-07-06 | — | — | US | disclosed |
| US-11548865-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | NOVARTIS AG (CH) | 2023-01-10 | — | — | US | disclosed |
| US-20210107889-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2021-04-15 | — | — | US | disclosed |
| WO-2021070090-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS AG (CH) | 2021-04-15 | — | — | WO | disclosed |
| EP-1626720-A1 | 4-(2-PHENYLSULFANYL-PHENYL)-PIPERIDINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | H. Lundbeck A/S (DK) | 2006-02-22 | — | — | EP | disclosed |
| WO-2006007843-A1 | 2-(1H-INDOLYLSULFANYL) -ARYL AMINE DERIVATIVES FOR USE IN THE TREATMENT OF AFFECTIVE DISORDERS, PAIN, ADHD AND STRESS URINARY INCONTINENCE | H. LUNDBECK A/S (DK) | 2006-01-26 | — | — | WO | disclosed |
| WO-2004087156-A1 | 4-(2-PHENYLSULFANYL-PHENYL)-PIPERIDINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | H. LUNDBECK A/S (DK) | 2004-10-14 | — | — | WO | disclosed |
| US-20030120070-A1 | Serotonin 5-HT1A and dopamin D2 receptor ligands | H. LUNDBECK A/S (DE) | 2003-06-26 | — | — | US | disclosed |
| US-6514993-B1 | Useful in the treatment of certain psychic and neurologic disorders | H. LUNDBECK A/S (DK) | 2003-02-04 | — | — | US | disclosed |
| CN-1067057-C | Serotonin 5-HT1A and dopamin D2 receptor ligands | LUNDBECK & CO AS H (DK) | 2001-06-13 | — | — | CN | disclosed |
| EP-0770066-B1 | SEROTONIN 5-HT 1A AND DOPAMIN D2 RECEPTOR LIGANDS | LUNDBECK & CO AS H (DK) | 2000-05-17 | — | — | EP | disclosed |
| CN-1154107-A | 5-hydroxytryptamine 5-HT1AAnd dopamine D2Receptor ligands | LUNDBECK & CO AS H (DK) | 1997-07-09 | — | — | CN | disclosed |
| EP-0770066-A1 | SEROTONIN 5-HT 1A AND DOPAMIN D2 RECEPTOR LIGANDS | H. LUNDBECK A/S (DK) | 1997-05-02 | — | — | EP | disclosed |
| WO-1995033729-A1 | SEROTONIN 5-HT1A AND DOPAMIN D2 RECEPTOR LIGANDS | H. LUNDBECK A/S (DK) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107889-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | CHRM2, CHRM1, CHRM3 | GPR119 43/4885TERT 4024/4885NAMPT 2543/4885 |
| US-20230257369-A1 | GLP-1R RECEPTOR AGONIST COMPOUND AND USE THEREOF | GLP1R, GIPR, GPR119 | GPR119 3/4885TERT 2632/4885NAMPT 2076/4885 |
| US-20230212139-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | CHRM2, CHRM1, CHRM3 | GPR119 43/4885TERT 4024/4885NAMPT 2543/4885 |
| US-11773087-B2 | GLP-1R receptor agonist compound and use thereof | GLP1R, GIPR, GPR119 | GPR119 3/4885TERT 2632/4885NAMPT 2076/4885 |
| US-11548865-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | CHRM2, CHRM1, CHRM3 | GPR119 43/4885TERT 4024/4885NAMPT 2543/4885 |
| US-20030120070-A1 | Serotonin 5-HT1A and dopamin D2 receptor ligands | HTR5A, HTR2C, HTR1D | GPR119 901/4885TERT 4397/4885NAMPT 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.